| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.048 | 0.4 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.042 | 0.4 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | -0.064 | 0.4 |
| mRNA | RDEA119 | FIMM | pan-cancer | AAC | -0.15 | 0.4 |
| mRNA | CCT007093 | GDSC1000 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | -0.042 | 0.4 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |